Cargando…
Post-transplant laronidase augmentation for children with Hurler syndrome: biochemical outcomes
Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). However, survivors remain burdened by substantial MPS-IH related residual disease. We studied the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme replacement...
Autores principales: | Lund, Troy C., Miller, Weston P., Liao, Ai Yin, Tolar, Jakub, Shanley, Ryan, Pasquali, Marzia, Sando, Nicole, Bigger, Brian W., Polgreen, Lynda E., Orchard, Paul J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773848/ https://www.ncbi.nlm.nih.gov/pubmed/31575939 http://dx.doi.org/10.1038/s41598-019-50595-1 |
Ejemplares similares
-
Clinical trial of laronidase in Hurler syndrome after hematopoietic cell transplantation
por: Polgreen, Lynda E., et al.
Publicado: (2019) -
Intrathecal enzyme replacement for Hurler syndrome: biomarker association with neurocognitive outcomes
por: Eisengart, Julie B., et al.
Publicado: (2019) -
Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation
por: Polgreen, Lynda E., et al.
Publicado: (2009) -
Hematopoietic stem cell transplant for Hurler syndrome: does using bone marrow or umbilical cord blood make a difference?
por: Orchard, Paul J., et al.
Publicado: (2022) -
Elevated cerebral spinal fluid biomarkers in children with mucopolysaccharidosis I-H
por: Raymond, Gerald V., et al.
Publicado: (2016)